<DOC>
	<DOCNO>NCT00176774</DOCNO>
	<brief_summary>This study examine investigational ( experimental ) agent Tetrathiomolybdate ( TM ) combine chemotherapy drug Irinotecan , 5-Fluorouracil ( 5-FU ) Leucovorin ( LV ) . This study evaluate safety tolerability combination drug use treatment metastatic colorectal cancer . This pilot clinical trial study reaction patient 's body tumor experimental treatment describe . The purpose study find kind side effect experimental treatment cause see often side effect occur .</brief_summary>
	<brief_title>Irinotecan , 5-Fluorouracil , Leucovorin Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Tetrathiomolybdate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>Patients must histologically prove adenocarcinoma primary colon rectum clinical pathologic evidence distant metastasis . Patients may receive adjuvant chemotherapy and/or one regimen chemotherapy metastatic disease . Patients must previously treat combination irinotecan/5FU/LV . Patients must past 18th birthday time enrollment . Patients must performance status 02 time registration . Patients must life expectancy &gt; 3 month . If patient undergone recent surgery , must fully recover effect surgery prior enrollment . Patients must pretreatment leukocyte count &gt; 3,000/l , absolute neutrophil count &gt; 1500/l , hemoglobin &gt; 8 mg/dl , platelet count &gt; 150,000/l within 2 week enrollment . Patients must adequate renal function , document serum creatinine &lt; 2.0 mg/dl , adequate hepatic function , document serum bilirubin &lt; 1.1 mg/dl within 2 week enrollment . Patients must active infection . Patients must serious medical psychiatric illness , treat study , would limit ability patient receive protocol therapy give inform consent . Patients must history active malignancy , treat study , within 12 month precede enrollment . Pregnant lactate woman may participate . Women reproductive age must undergo serum pregnancy test within 14 day enrollment . Men woman reproductive potential must use effective contraceptive method study . There must plan patient receive concomitant antineoplastic therapy protocol . All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>